| Ticagrelor. | |
| | |
MedLine Citation:
|
PMID: 21455230 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Ticagrelor (Brilique; AstraZeneca), an oral antiplatelet therapy, was granted marketing authorization by the European Commission in December 2010 for the prevention of atherothrombotic events in adult patients with acute coronary syndromes. |
| | |
Authors:
|
Kurt Huber; Bashar Hamad; Peter Kirkpatrick |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Nature reviews. Drug discovery Volume: 10 ISSN: 1474-1784 ISO Abbreviation: Nat Rev Drug Discov Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-04-01 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101124171 Medline TA: Nat Rev Drug Discov Country: England |
Other Details:
|
Languages: eng Pagination: 255-6 Citation Subset: IM |
Affiliation:
|
3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, Montleartstrasse 37, A-1160 Vienna, Austria. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Crowd sourcing in drug discovery.
Next Document: Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?